Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

848 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Essence Trial: Efficacy and Safety of Subcutaneous Enoxaparin in Unstable Angina and Non-Q-Wave MI: A Double-Blind, Randomized, Parallel-Group, Multicenter Study Comparing Enoxaparin and Intravenous Unfractionated Heparin: Methods and Design.
Cohen M, Blaber R, Demers C, Gurfinkel EP, Langer A, Fromell G, Premmereur J, Turpie AG. Cohen M, et al. Among authors: langer a. J Thromb Thrombolysis. 1997;4(2):271-274. doi: 10.1023/a:1008803203290. J Thromb Thrombolysis. 1997. PMID: 10639269
A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group.
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. Cohen M, et al. Among authors: langer a. N Engl J Med. 1997 Aug 14;337(7):447-52. doi: 10.1056/NEJM199708143370702. N Engl J Med. 1997. PMID: 9250846 Free article. Clinical Trial.
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KA, Premmereur J, Bigonzi F. Cohen M, et al. Among authors: langer a. Am J Cardiol. 1998 Sep 10;82(5B):19L-24L. doi: 10.1016/s0002-9149(98)00108-8. Am J Cardiol. 1998. PMID: 9737476 Clinical Trial.
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events.
Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Le Iouer V, Fromell GJ, Demers C, Turpie AG, Califf RM, Fox KA, Langer A. Goodman SG, et al. Among authors: langer a. J Am Coll Cardiol. 2000 Sep;36(3):693-8. doi: 10.1016/s0735-1097(00)00808-1. J Am Coll Cardiol. 2000. PMID: 10987586 Free article. Clinical Trial.
One-year follow-up of the ASSENT-2 trial: a double-blind, randomized comparison of single-bolus tenecteplase and front-loaded alteplase in 16,949 patients with ST-elevation acute myocardial infarction.
Sinnaeve P, Alexander J, Belmans A, Bogaerts K, Langer A, Diaz R, Ardissino D, Vahanian A, Pehrsson K, Armstrong P, Van de Werf F; ASSENT-2 Investigators. Sinnaeve P, et al. Among authors: langer a. Am Heart J. 2003 Jul;146(1):27-32. doi: 10.1016/S0002-8703(03)00117-0. Am Heart J. 2003. PMID: 12851604 Clinical Trial.
848 results